Grogan Donna Roy Purchases 62,000 Shares of C4 Therapeutics
Grogan Donna Roy acquired 62,000 shares of C4 Therapeutics on June 24, 2026.
Key Points
- Grogan Donna Roy bought 62,000 shares of C4 Therapeutics, Inc. on June 24, 2026.
- Shares of C4 Therapeutics traded near $4.40 on Saturday with a market cap of $471 million.
- Analysts maintain a strong buy consensus with a mean price target of $13.33.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Grogan Donna Roy recently purchased 62,000 shares of C4 Therapeutics, Inc. (NasdaqGS: CCCC) on June 24, 2026. The transaction wasn't carried out under a pre-planned trading scheme, indicating a direct acquisition of shares.
Insider Buying and Selling at C4 Therapeutics, Inc.
Several insiders, including Steven Hoerter, Laura Bessen, Stephen Fawell, Owen Hughes, and Donna Roy Grogan, each bought 62,000 shares of C4 Therapeutics on June 24, 2026. Kenneth Carl Anderson also made a smaller purchase of 1,070 shares on June 1, 2026, at $2.11 per share.
C4 Therapeutics, Inc. Stock Up 14.3%
Shares of C4 Therapeutics traded near $4.40 on Saturday. The company, with a market cap of approximately $471 million, operates in the biotechnology sector. It has a forward P/E ratio of -4.10, indicating losses, and a beta of 2.93, suggesting higher volatility. The stock's 52-week range is between $1.40 and $4.60, with moving averages of $3.51 for 50 days and $2.70 for 200 days. C4 Therapeutics has a strong liquidity position with a current ratio of 9.01 and a quick ratio of 8.76.
$CCCC stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 1, 2026, Evercore ISI Group maintained its buy rating for C4 Therapeutics with a price target of $12. Barclays and Brookline Capital have also maintained their buy ratings, with targets of $7 and $30, respectively. The consensus among analysts is a strong buy, with a mean price target of $13.33 based on six opinions.
About C4 Therapeutics
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing therapies that degrade disease-causing proteins. Its lead product, Cemsidomide, targets multiple myeloma, while other candidates like CFT8919 address non-small cell lung cancer. The company collaborates with major partners like Roche and Merck to advance its therapeutic pipeline.
Bottom Line
Grogan Donna Roy's recent acquisition of 62,000 shares of C4 Therapeutics reflects insider interest in the company. Investors often track such insider activities for insights into potential company performance. However, it's important to remember that insider trades and analyst ratings are just pieces of the broader investment puzzle.
Get C4 Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CCCC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.